Uzawa A, Akamine H, Kojima Y, et al. - In the present study, the researchers sought to assess the clinical significance of serum interleukin-6 (IL-6) level as a biomarker of disease activity in patients with an anti-acetylcholine receptor (AChR) antibody-positive myasthenia gravis (MG). Serum IL-6 levels were measured in 93 treatment-naïve patients with anti-AChR antibody-positive MG and contrasted with those in 101 controls. Furthermore, correlations between serum IL-6 levels and clinical characteristics were investigated. Findings suggested that IL-6 plays a role in the pathogenesis of anti-AChR antibody-positive MG and might be a therapeutic target in MG.